Scholer” from its public image, changing its brand name, email addresses and web domain", while retaining the legal entity name in full. Notable mandates Transactional Representing Skilled Healthcare Group, Inc. in its definitive agreement to combine with Genesis HealthCare, one of the nation's largest providers of post-acute care services. Advised Sapheon, Inc., a privately held developer of venous disease treatments, in its acquisition by Covidien plc. Advised longtime client Pfizer Inc. in its agreement to acquire InnoPharma, Inc., a privately held pharmaceutical development company. Advised VanDeMark Chemical Inc., the largest, independent manufacturer of phosgene and phosgene derivatives in North America, in its acquisition of Framochem Kft from ISOCHEM S.A.S., a company belonging to Germany's AURELIUS Group, and the related debt and equity financings in connection with the acquisition. Advised ultra premium tequila brand Avion Tequila in its agreement to sell a majority stake in the Avion Spirits LLC joint venture to Pernod Ricard USA. Represented Healthy Directions, LLC along with its equity holders, including longtime clients American Securities and ACI Capital, in the recently announced sale of Healthy Directions to Helen of Troy Limited. Represented leading private equity firm American Securities in its acquisition, from Morgan Stanley Global Private Equity, of Learning Care Group (US) Inc. in partnership with the Company's management team. Represented Omega Healthcare Investors, Inc. as the borrower in a $1.2 billion unsecured syndicated credit facility with Bank of America, N.A., as administrative agent, and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as joint lead arranger and sole book runner. Advised real estate investment trust Five Oaks Investment Corp (FOIC) (NYSE: OAKS) in a $75 million at-the-market (ATM) facility launched on May 30, 2014 with Mitsubishi UFJ Securities (USA) Inc, BTIG LLC and Keefe, Bruyette & Woods Inc. Advised Novartis on the intellectual property-related aspects of a series of strategic deals totaling $30 billion, including the landmark acquisition of GlaxoSmithKline's oncology unit for up to $16 billion. Advised the shareholders of German pharmaceutical company Activaero GmbH, Gmünden in the sale of all their shares to Vectura Group plc for a total of €130 million, funded through a combination of cash payments and Vectura shares. Advised the shareholders of Pharmalink Consulting, a leading global provider of regulatory affairs consulting services to the life sciences industry, on the sale of the company to business processes and operations provider Genpact Ltd. Represented Onex Corporation and The Warranty Group in the